Summary We report the first demonstration of the biotransformation of the anti-cancer drug 5-fluorouracil (FU) into two new metabolites, a-fluoro-f-hydroxypropionic acid (FHPA) and fluoroacetate (FAC), in the isolated perfused rat liver (IPRL) and in the rat in vivo. IPRL was perfused with solutions of pure FU at two doses, 15 or 45 mg kg-' body weight, and rats were injected i.p. with 180 mg of FU kg-' body weight.
Summary We report the first demonstration of the biotransformation of the anti-cancer drug 5-fluorouracil (FU) into two new metabolites, a-fluoro-f-hydroxypropionic acid (FHPA) and fluoroacetate (FAC) , in the isolated perfused rat liver (IPRL) and in the rat in vivo. IPRL was perfused with solutions of pure FU at two doses, 15 or 45 mg kg-' body weight, and rats were injected i.p. with 180 mg of FU kg-' body weight.
Fluorine-19 NMR analysis of perfusates from IPRL and rat urine showed the presence of the normal metabolites of FU and low amounts of FHPA (0.4% or 0.1% of injected FU in perfusates from IPRL treated with 15 or 45 mg of FU kg-' body weight, respectively; 0.08% of the injected FU in rat urine) and FAC (0.1% or 0.03% of injected FU in perfusates from IPRL treated with 15 or 45 mg of FU kg-' body weight, respectively; 0.003% of the injected FU in rat urine). IPRL was also perfused with a solution of a-fluoro-i-alanine (FBAL) hydrochloride at 16.6 mg kg-' body weight dose equivalent to 15 mg of FU kg-' body weight. Low amounts of FHPA (0.2% of injected FBAL) and FAC (0.07%) were detected in perfusates, thus demonstrating that FHPA and FAC arise from FBAL catabolism. As FAC is a well-known cardiotoxic poison, and FHPA is also cardiotoxic at high doses, the cardiotoxicity of FU might stem from at least two sources. The first one, established in previous papers (Lemaire et al, 1992 (Lemaire et al, , 1994 , is the presence in commercial solutions of FU of degradation products of FU that are metabolized into FHPA and FAC; these are formed over time in the basic medium necessary to dissolve the drug. The second, demonstrated in the present study, is the metabolism of FU itself into the same compounds.
Keywords: 5-fluorouracil; a-fluoro-J-alanine; '9F nuclear magnetic resonance; metabolism; fluoroacetate; a-fluoro-o-hydroxypropionic acid; isolated perfused rat liver; rat urine 5-Fluorouracil (FU) is widely used as an anti-tumour agent for treatment of solid tumours. Its chief side-effects are myelosuppression, diarrhoea, vomiting and mucositis. However, over the last decade, the number of reports of cardiotoxicity and neurotoxicity attributed to FU has rapidly increased, probably because of the use of higher doses in continuous perfusion (Moertel et al, 1964; Rezkalla et al, 1989 ; Moore et al, 1990; Gamelin et al, 1991; De Fomi et al, 1992; Robben et al, 1993; Anand, 1994 ). The precise biochemical mechanism underlying these two side-effects remains unclear, although several investigators have postulated, but never demonstrated experimentally, that FU might be transformed into fluoroacetate (FAC), a highly cardiotoxic and neurotoxic poison (Koenig and Patel, 1970; Okeda et al, 1990) . FAC enters the Krebs cycle and is then transformed into fluorocitrate, which inhibits the enzyme aconitase. Aconitase catalyses the conversion of citrate to isocitrate via the obligatory intermediate cis-aconitate. Inhibition of aconitase leads to a build-up of citrate in animal tissues (in particular heart) and serum, and the heart production of ATP is severely limited. Toxicity and death are thought to be caused by severe impairment of energy production (Pattison and Peters, 1966; Bosakowski and Levin, 1986; Keller et al, 1996) .
Having at our disposal a powerful method for studying the metabolism of fluorinated drugs, in particular fluoropyrimidines we have been able to demonstrate, using fluorine-19 nuclear magnetic resonance ('9F-NMR), the biotransformation of FU into two new metabolites, a-fluoro-,-hydroxypropionic acid (FHPA) and FAC, in the isolated perfused rat liver (IPRL) and in the rat in vivo. This transformation occurs via a-fluoro-p-alanine (FBAL), the main catabolite of FU.
MATERIALS AND METHODS Chemicals
FU, FAC and bovine albumin (fraction V) powder (ref. A9647) were purchased from Sigma and chromium (III) acetylacetonate (Cr(acac)3) from Aldrich (all from Sigma-Aldrich Chimie, 38297 Saint-Quentin Fallavier, France). FBAL hydrochloride was provided by Tokyo Kasei Chemicals, Tokyo, Japan. 5,6-Dihydro-6-hydroxy-5-fluorouracil (FUOH) was supplied by PCR, Gainesville, FL, USA. All other chemicals were reagent grade and obtained from standard commercial sources.
Synthesis of FHPA FUOH (6.7 mg, 45 , umol) was dissolved in 12 ml of 1 M potassium hydroxide at ambient temperature and the mixture was stirred for 1 h (Lozeron et al, 1964 a 'F-NMR 6 are related to external trifluoroethanoic acid (5% (w/v) aqueous solution). bd, Doublet; t, triplet. cThe slight differences in the J values are due to the low digital resolution of the spectra (1.3 Hz per point). (MaletMartino and Martino, 1992) , -3 ,UM with a 9.4-Tesla spectrometer (Kamm et al, 1996) , -1-2 ,UM with a 11.7-Tesla spectrometer (Hull et al, 1988) . As FHPA and FAC concentrations did not reach this limit in the non-concentrated perfusates (maximal concentrations <2 g1M for FHPA and <1 ,UM for FAC as estimated from assay of concentrated perfusates), these compounds were not detectable. We therefore determined their concentrations from the spectra of the concentrated perfusates in which FHPA and FAC concentrations were .10 gIM and thus could be accurately assayed.
RESULTS
IPRL experiments with FU or FBAL Qualitative analysis IPRL were treated with pure FU at two doses, 45 mg kg-' body weight (n = 4) or a 'therapeutic' dose of 15 mg kg-' body weight (n = 5) for 3 h.
Metabolism of 5-fluorouracil into fluoroacetate in rats 83 (Martino et al, 1987) at -110.9 p.p.m. and fluoride ion (F-) from the defluorination of FBAL (Martino et al, 1985; Porter et al, 1995) at -43.5 p.p.m. A weak additional signal at -110.1 p.p.m. corresponding to an unknown compound was observed in the spectra of perfusates from experiments at 45 mg of FU kg-' body weight and in one out of the five experiments at 15 mg of FU kg-1 body weight. 5,6-Dihydro-5-fluorouracil (FUH2) was not observed in any of the experiments (Figure 1) .
A characteristic '9F-NMR spectrum of a concentrated perfusate from an IPRL treated with FU (Figure 2) 
Quantitative analysis
We determined the amounts of unmetabolized FU (in the 45 mg of FU kg-' body weight experiments), its different catabolites (FUPA, CFBAL, FBAL, F-) and the unknown compound at -110.1 p.p.m. from the values measured in the non-concentrated perfusates. For FBAL experiments, the amounts of unmetabolized FBAL and Fwere determined in the non-concentrated perfusates. As FHPA and FAC were not detectable in the non-concentrated perfusates, we determined their concentrations from the spectra of the concentrated perfusates. It should be noted that the amounts of FHPA and FAC were underestimated as demonstrated previously (Arellano et al, 1997) . Table 2 shows the results of the IPRL experiments. All FU was metabolized at the 15 mg kg-' body weight dose, whereas at 45 mg kg-' body weight only 3 ± 4% of the injected FU was recovered unchanged in the perfusate. The amount of total catabolites (FUPA + CFBAL + FBAL + F-+ the compound resonating at -110.1 p.p.m. when present) increased as a direct function of the injected FU dose. At 45 mg of FU kg-' body weight, FBAL was by far the main catabolite as it represented 91% of the metabolites of FU whereas F-made up only 6%. At 15 mg of FU kg-' body weight, FBAL and F-represented 58% and 41%, respectively, of FU metabolites. Only small amounts of FHPA and FAC were found in the perfusates: FHPA represented 0.4% or 0.1% and FAC 0.1% or 0.03% of the injected FU (15 or 45 mg of FU kg-' body weight respectively). There was no significant difference in the amounts for the two doses of FU (Student's t-test, 0.05 < P < 0.1 for FHPA and 0.1 < P < 0.375 for FAC).
M Arellano et al
In FBAL experiments, F-was the main metabolite and represented 16% of the injected FBAL dose. (Lemaire et al, 1992 (Lemaire et al, , 1994 indicated that the cardiotoxicity of FU was due, at least in the isolated perfused rabbit heart model, to degradation compounds of this drug, namely fluoromalonic acid semi-aldehyde (FMASAld) and fluoroacetaldehyde (Facet) . These are found in commercial solutions and are formed over time in the basic medium required to dissolve FU. FMASAId is chemically transformed into Facet, which is extensively metabolized into FAC. Thus, the solutions of FU injected in IPRL or in rats had to be initially devoid of these two compounds. Mukherjee and Heidelberger (1960) (1992) , using high-performance liquid chromatography (HPLC), only detected FBAL in urine and detected mainly conjugates of FBAL with bile acids in the liver. Using '9F-NMR, Hull et al (1988) detected FHPA in the urine of patients treated with FU, although they referred to it as compound U2 and it was not identified. Two explanations could account for these observations. The first is that only small amounts of FHPA and FAC are formed. The second is that chromatographic determination of FAC involves complex and specific methodological procedures (Ray et al, 1981; Okuno et al, 1982; Kramer, 1984; Ozawa and Tsukioka, 1987; Burke et al, 1989; Mori et al, 1996 (Porter et al, 1995) . The literature on the inhibitory effect of P-fluoro-a-amino acids on transaminase reactions (Walsh, 1983) indicates that the Schiff's base intermediate formed with the pyridoxal phosphate cofactor of these enzymes can eliminate HF to form an enamine that deactivates the enzyme. Moreover, a ,B-alanine transaminase has been isolated from Streptomyces griseus and was found to be fully inhibited after incubation with FBAL (Yonaha et al, 1985) . It was therefore possible to envisage that the large amounts of FBAL formed in our experiments with FU at 45 mg kg-' body weight could inactive the defluorinating enzyme. However, Porter et al (1995) reported that
AlaAT-II purified from rat liver was not inactivated significantly during 1 h of FBAL dehalogenation. To explain our data, one might therefore evoke that either the behaviour of the enzyme is different for longer periods of time (3 h in our experiments) or other(s) pyridoxal phosphate enzyme(s) is(are) involved in FBAL defluorination, as already suggested (Spears et al, 1990; Porter et al, 1995) . Although we have no evidence of an identical cell penetration of the two FBAL enantiomers, the slightly lower amount of F formed in the experiments with [RS]-FBAL relative to the experiments with FU at 15 mg kg-' body weight (Table 2 ) is in agreement with the report that [R]-FBAL was the preferred enantiomer for the defluorinating activity in rat liver homogenates (Porter et al, 1995 (1998) 77(1), [79] [80] [81] [82] [83] [84] [85] [86] . Cancer Research Campaign 1998
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at 15 mg of FU kg-' body weight, has not been identified. Its chemical shift led us to propose that it corresponds to a compound resulting from an interaction of FBAL involving its amino group with a constituent of the perfusion medium that could have been liberated by the liver. We have already detected this kind of compound in plasma containing FBAL (Martino et al, 1987) . The higher level of FBAL could explain the higher level of this compound in the experiments at 45 mg of FU kg-' body weight.
By analogy with the metabolism of P-alanine (Griffith, 1986) , we propose the following scheme for the metabolism of FBAL. The enzymes of 1-alanine catabolism are probably also involved in the catabolism of FBAL. FMASAld and Facet were not detected in our experiments as they are very reactive. The spontaneous decarboxylation of malonic acid semi-aldehyde, the non-fluorinated analogue of FMASAld, is well documented (Pihl and Fritzson, 1955) . During the metabolization of fluorinated ethanes into FAC in rats, intermediate Facet was also undetected in urine and kidney extracts (Keller et al, 1996) .
The first step in f-alanine catabolism is a transamination reaction to form malonic acid semi-aldehyde catalysed by hepatic transaminases, namely 3-alanine-pyruvate aminotransferase (EC 2.6.1.18), f-alanine-oxoglutarate aminotransferase (EC 2.6.1.19) and D-3-aminoisobutyrate-pyruvate aminotransferase (EC 2.6.1.40) (Griffith, 1986; Tamaki et al, 1990) . Even if we found no evidence of this assertion in literature, the low levels of FHPA and FAC obtained in our experiments are probably as a result of FBAL being is a poor substrate for one or several enzymes of the catabolic pathway of 3-alanine. Moreover, it has been reported that FU is a competitive inhibitor of EC 2.6.1.19 and EC 2.6.1.40 with respect to 3-alanine while FBAL inactivates EC 2.6.1.40 (Kaneko et al, 1992) . The larger amount of injected FU in IPRL experiments at 45 mg kg-' body weight could thus explain that there is no relationship between the doses of injected FU and the amounts of FHPA and FAC formed. The levels of FHPA and FAC obtained in the experiments with FBAL were nearly half the amounts formed in the experiments with FU at 15 mg kg-' body weight (Table 2) . This is probably due to the metabolization of the sole [R] enantiomer, which is the enantiomer formed during the metabolization of FU (Gani et al, 1985) .
FAC is a highly cardiotoxic and neurotoxic poison (Pattison and Peters, 1966) . FHPA does not generate cardiotoxic symptoms on the isolated perfused rabbit heart model at a dose of 0.09 gmol kg-' body weight but is highly cardiotoxic on this model at a high dose (14 ,umol kg-' body weight) (unpublished results). The levels of FAC and FHPA found in perfusates of rat livers and in rat urine were low. However, as the patients are normally treated for several days (even weeks) with FU at the therapeutic dose of 15 mg kg-', and as FAC is known to accumulate in the organism (Meldrum and Bignell, 1957) , a cumulative toxicity of FAC (and possibly also FHPA) could explain cardio-and/or neurotoxic effects of FU in patients. Moreover , it has been demonstrated that FBAL, the precursor of FHPA and FAC, accumulated in rats and was retained up to 8 days in various tissues, mainly liver, heart and brain (Zhang et al, 1992) . FBAL may well be further metabolized in these tissues over long periods of time. These observations could account for the delayed onset of cardiotoxic or neurotoxic symptoms with respect to the beginning of treatment in patients receiving FU (Moore et al, 1990; Anand, 1994) .
The results of the present study along with those of two previous ones (Lemaire et al, 1992 (Lemaire et al, , 1994 show that the cardiotoxicity of FU might have at least two origins. The first is the presence of fluorinated impurities in commercial solutions of FU derived from the degradation of FU in the basic medium required for its solubilization, which are metabolized into FHPA and FAC. The second is the metabolism of FU itself into these two cardiotoxic compounds. We have demonstrated the presence of FAC and FHPA in urine of patients treated with FU (Lemaire et al, 1992 (Lemaire et al, , 1996 . As FU solutions are not pure, FAC and FHPA could arise from both the metabolization of impurities and the metabolism of FU itself. We have shown that a part of FHPA came from FU metabolism but we could not demonstrate it for FAC (Lemaire et al, 1996) .
On the basis of our results, the cardiotoxicity (and possibly the neurotoxicity) of FU could be attenuated by: (1) using formulations that are made up immediately before injection to avoid degradation of FU in solution (a lyophilisate form for example); and (2) the use of an inhibitor of the catabolism of FU (e.g. ethynyluracil (Baccanari et al, 1993) to prevent formation of FBAL and its subsequent metabolization into the toxic FHPA and FAC. 
